WO2008110872A3 - Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses - Google Patents

Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses Download PDF

Info

Publication number
WO2008110872A3
WO2008110872A3 PCT/IB2007/004522 IB2007004522W WO2008110872A3 WO 2008110872 A3 WO2008110872 A3 WO 2008110872A3 IB 2007004522 W IB2007004522 W IB 2007004522W WO 2008110872 A3 WO2008110872 A3 WO 2008110872A3
Authority
WO
WIPO (PCT)
Prior art keywords
solvent
agent
composition
group
nitric oxide
Prior art date
Application number
PCT/IB2007/004522
Other languages
French (fr)
Other versions
WO2008110872A2 (en
Inventor
Dov Tamarkin
Meir Eini
Doron Friedman
Tal Berman
Alex Besonov
Original Assignee
Foamix Ltd
Dov Tamarkin
Meir Eini
Doron Friedman
Tal Berman
Alex Besonov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foamix Ltd, Dov Tamarkin, Meir Eini, Doron Friedman, Tal Berman, Alex Besonov filed Critical Foamix Ltd
Publication of WO2008110872A2 publication Critical patent/WO2008110872A2/en
Publication of WO2008110872A3 publication Critical patent/WO2008110872A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Abstract

The present invention relates to a foamable therapeutic composition comprising: (a) a therapeutically effective concentration of at least one active agent selected from the group consisting of a channel agent, a cholinergic agent, and a nitric oxide donor; and (b) a foamable carrier comprising: i. about 50% to about 98% of a solvent selected from the group consisting of water; a hydrophilic solvent; a hydrophobic solvent; a potent solvent; a polar solvent, a silicone, an emollient, and mixtures thereof; ii. 0% to about 48% of a secondary solvent selected from the group consisting of water; a hydrophilic solvent; a hydrophobic solvent; a potent solvent; a polar solvent, a silicone, an emollient, a co-solvent, a penetration enhancer and mixtures thereof; iii. a surface-active agent; iv. about 0% to about 5% by weight of at least one polymeric agent; and v. a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition; wherein the composition is housed in a container and is substantially flowable, and which upon release expands to form a breakable foam; and wherein the foamable carrier is selected to generate a foam of good to excellent quality. The invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject, comprising administering such a composition to an afflicted target site.
PCT/IB2007/004522 2006-06-23 2007-06-22 Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses WO2008110872A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81594806P 2006-06-23 2006-06-23
US60/815,948 2006-06-23

Publications (2)

Publication Number Publication Date
WO2008110872A2 WO2008110872A2 (en) 2008-09-18
WO2008110872A3 true WO2008110872A3 (en) 2009-06-25

Family

ID=39705041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/004522 WO2008110872A2 (en) 2006-06-23 2007-06-22 Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses

Country Status (1)

Country Link
WO (1) WO2008110872A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8741265B2 (en) 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
EP1556009B2 (en) 2002-10-25 2021-07-21 Foamix Pharmaceuticals Ltd. Cosmetic and pharmaceutical foam
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
WO2006100154A1 (en) 2005-03-24 2006-09-28 Nolabs Ab Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor
US20080260655A1 (en) * 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
CA2760186C (en) 2009-04-28 2019-10-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA3062005C (en) * 2009-08-21 2022-02-15 Novan, Inc. Topical gels comprising nitric oxide-releasing polysiloxane macromolecules and uses thereof
CN102695528B (en) 2009-08-21 2016-07-13 诺万公司 Wound dressing, its using method and forming method thereof
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
IT1397000B1 (en) * 2009-11-12 2012-12-20 Antropoli USE OF A PREPARATION BASED ON NIFEDIPINE FOR THE TREATMENT OF VAGINISM
JP6277124B2 (en) 2011-07-05 2018-02-07 ノヴァン，インコーポレイテッド Topical composition
WO2013006613A1 (en) 2011-07-05 2013-01-10 Novan, Inc. Methods of manufacturing topical compositions and apparatus for same
WO2013067591A1 (en) * 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
EP2833721B1 (en) 2012-03-14 2021-02-17 Novan Inc. Nitric oxide releasing pharmaceutical compositions
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
WO2015021382A2 (en) 2013-08-08 2015-02-12 Novan, Inc. Topical compositions and methods of using the same
MX2016014913A (en) 2014-05-15 2017-04-11 Gruenenthal Gmbh Device and formulation for topical treatment of pain affecting the vulvar area of the female human genital organ.
US10322081B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
US10925689B2 (en) 2014-07-14 2021-02-23 Novan, Inc. Nitric oxide releasing nail coating compositions, nitric oxide releasing nail coatings, and methods of using the same
EP3177262A4 (en) 2014-08-08 2018-04-18 Novan Inc. Topical emulsions
US9895311B2 (en) * 2014-09-25 2018-02-20 Pharmiva Ab Foam-forming compositions and methods for delivering an active to a body cavity
US10849864B2 (en) 2015-07-28 2020-12-01 Novan, Inc. Combinations and methods for the treatment and/or prevention of fungal infections
US10052348B2 (en) 2016-01-27 2018-08-21 Syk Technologies, Llc Nitric oxide topical application apparatus and methods
EP3423100A4 (en) 2016-03-02 2019-10-16 Novan, Inc. Compositions for treating inflammation and methods of treating the same
CN116585257A (en) 2016-04-13 2023-08-15 诺万公司 Compositions, systems, kits and methods for treating infections
MX2020012139A (en) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Compositions and methods for treating rosacea and acne.
US11285171B2 (en) 2018-03-01 2022-03-29 Novan, Inc. Nitric oxide releasing suppositories and methods of use thereof
FR3092247B1 (en) * 2019-01-31 2022-07-08 Oreal Cosmetic composition comprising anti-hair loss active agents, thickening polymers, nonionic surfactants and propellants, and method for cosmetic treatment
WO2020245574A1 (en) 2019-06-04 2020-12-10 Thirty Respiratory Limited Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract
CN114206325A (en) 2019-06-04 2022-03-18 三十控股有限公司 Methods and compositions for generating nitric oxide and uses thereof
WO2021214439A1 (en) 2020-04-23 2021-10-28 Thirty Respiratory Limited Methods and compositions for treating and combatting tuberculosis
EP4138795A1 (en) 2020-04-23 2023-03-01 Thirty Respiratory Limited Nitric oxide or nitric oxide releasing compositions for use in treating sars-cov and sars-cov-2
CN112402615A (en) * 2020-11-11 2021-02-26 长沙晶易医药科技有限公司 Compound external preparation for treating alopecia areata and preparation method thereof
WO2022150415A1 (en) * 2021-01-06 2022-07-14 The Penn State Research Foundation Methods and materials for treating hair loss
CN113180060B (en) * 2021-05-10 2022-06-17 西南大学 Scoparone acaricide stored at normal temperature and preparation method thereof
CN114870016B (en) * 2022-04-21 2023-05-26 上海博悦生物科技有限公司 Micro-emulsion foaming agent of JAK inhibitor and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001863A1 (en) * 1986-09-12 1988-03-24 The Upjohn Company Foams for delivery of minoxidil
WO2003055454A1 (en) * 2001-12-21 2003-07-10 Ponsus Pharma Ab New composition
US20050031547A1 (en) * 2003-08-04 2005-02-10 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
WO2005018530A2 (en) * 2003-08-25 2005-03-03 Foamix Ltd. Penetrating pharmaceutical foam
US20050079139A1 (en) * 2003-10-11 2005-04-14 Jacques Elizabeth Joan Minoxidil pharmaceutical foam formulation
US20050271596A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001863A1 (en) * 1986-09-12 1988-03-24 The Upjohn Company Foams for delivery of minoxidil
WO2003055454A1 (en) * 2001-12-21 2003-07-10 Ponsus Pharma Ab New composition
US20050271596A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
US20050031547A1 (en) * 2003-08-04 2005-02-10 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
WO2005018530A2 (en) * 2003-08-25 2005-03-03 Foamix Ltd. Penetrating pharmaceutical foam
US20050079139A1 (en) * 2003-10-11 2005-04-14 Jacques Elizabeth Joan Minoxidil pharmaceutical foam formulation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8741265B2 (en) 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence

Also Published As

Publication number Publication date
WO2008110872A2 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
WO2008110872A3 (en) Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
WO2007085902A3 (en) Foamable composition combining a polar solvent and a hydrophobic carrier
WO2006003481A3 (en) Oleaginous pharmaceutical and cosmetic foam
WO2009090495A3 (en) Oil and liquid silicone foamable carriers and formulations
WO2009098595A3 (en) Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
ES2364692T3 (en) ESSENTIALLY FREE FOAM COMPOSITION OF PHARMACEUTICALLY ACTIVE INGREDIENTS FOR HUMAN SKIN TREATMENT.
DK2494959T3 (en) Foam Bart dicarboxylsyrebærestof and pharmaceutical compositions thereof
ES2918299T3 (en) High oil content emollient spray foam compositions
US20110052506A1 (en) Stable Aerosol Topical Foams Comprising a Hypochlorite Salt
CA2752070C (en) Foamable benzoyl peroxide compositions for topical administration
WO2007054818A3 (en) Foamable vehicle and pharmaceutical compositions thereof
WO2008075207A3 (en) Anti-infection augmentation foamable compositions and kit and uses thereof
BRPI0509708A (en) pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and / or medium chain triglycerides
TW200420303A (en) Clindamycin phosphate foam
US20120148516A1 (en) Tandem Hypochlorite-Barrier Repair Therapy for the Treatment of Eczema
US20090232743A1 (en) Foamable Microemulsion Compositions for Topical Administration
BRPI0510840A (en) pharmaceutical composition, pressurized composition, aerosol pump and use of a vitamin D analog mixture and a corticosteroid
WO2007023396A3 (en) Vasoactive kit and composition and uses thereof
ZA200510388B (en) Foamable pharmaceutical compositions and methods for treating a disorder
WO2007085899A3 (en) Foamable arthropocidal composition for tropical application
WO2008152444A3 (en) Foamable waterless compositions with modulating agents
WO2013067271A2 (en) Stable dermatological aerosol foams utilizing reactive propellants
SG156624A1 (en) Organo-gel formulations for therapeutic applications
EP2100601A3 (en) Topical pharmaceutical foam composition
EP2029106A2 (en) Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07872837

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07872837

Country of ref document: EP

Kind code of ref document: A2